No data is captured relating to the clinical indication a prescription is intended for. Some antidepressant drugs can be used for a variety of clinical indications and therefore the figures provided may include items which may have been prescribed for a different condition. The list of antidepressants which have been identified for this response are those listed within British National Formulary (BNF) chapter 4 section 3 (Antidepressant Drugs).

The NHS Business Services Authority only holds data relating to patient ages from April 2015. Therefore, the data attached is for the three full years for which there is data available.

No data is captured relating to the clinical indication a prescription is intended for. Some antidepressant drugs can be used for a variety of clinical indications and therefore the figures provided may include items which may have been prescribed for a different condition. The list of antidepressants which have been identified for this response are those listed within British National Formulary (BNF) chapter 4 section 3 (Antidepressant Drugs).

The NHS Business Services Authority only holds data relating to patient ages from April 2015. Therefore, the data attached is for the three full years for which there is data available.

The number of prosecutions, convictions, sentences, compensation orders and average compensation amount for child sex abuse offences in 2018 can be viewed in the table attached.

The number of prosecutions, convictions, sentences, compensation orders and average compensation amount for child sex abuse offences in 2018 can be viewed in the table attached.

The Government are prioritising support for victims through the criminal justice system and beyond, and we are committed to tackling poor criminal justice outcomes for them. Just last month, my right hon. Friend the Lord Chancellor and I took part in a roundtable at Downing Street to discuss support for victims of rape. Victims and stakeholders highlighted the importance of support in their engagement with the criminal justice system.

Following publication of the interim People Plan on 3 June 2019, work is now underway to develop a full five-year NHS People Plan, which will support delivery of the NHS Long Term Plan. The full People Plan will build on the ambitions in the interim Plan, focusing on education and training, and new routes into the National Health Service, as well as workforce planning and redesign, and workforce productivity (releasing time for care).

Since publication of the Interim Plan, Health Education England and NHS Improvement and NHS England have been working together to ensure delivery of the immediate actions and have been working with stakeholders including the People Plan advisory group and trade unions, think tanks, academia, and professional bodies to develop the full People Plan. Work is also underway with national clinical programmes, including cancer and diagnostics, to understand their workforce priorities for delivering the Long Term Plan commitments, including addressing key workforce shortages.

Also, as part of the NHS Long Term Plan, NHS England asked Sir Mike Richards to lead a review to improve the delivery of the screening programmes, increase uptake, learn the lessons from the recent issues around breast and cervical screening, and modernise and expand diagnostic capacity. Workforce requirements to support delivery of our national screening programmes are included in scope of Professor Sir Mike Richards review and we expect publication of the report shortly. The review, will make recommendations to the Secretary of State and Board of NHS England about the future commissioning and delivery of screening programmes in England.

This information is not collected centrally.

The requested information is attached.

The requested information is attached.

The requested information is attached.

There is currently no overall waiting time standard for children and young people’s mental health services and therefore this information is not collected centrally. However, there are two waiting time standards which apply to specific areas. The first standard is for young people’s eating disorder services, which is that urgent cases should be seen within one week and non-urgent cases within four weeks. The latest data (for quarter 4 of 2018/19) shows that 80.6 % of children and young people with eating disorders were seen within one week (urgent) and 82.4 % of children and young people with eating disorders were seen within four weeks (routine).

The second standard is for first episode of psychosis, where a patient should be seen within two weeks. This standard was met in 75.3% of cases although the data refers to patients of all ages and is not available by age group.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

The information requested is not available.

The Criminal Injuries Compensation Authority does not ask an applicant to provide their occupation when applying for compensation.

The information requested is not available.

The Criminal Injuries Compensation Authority does not ask an applicant to provide their occupation when applying for compensation.

The information requested is not available.

The Criminal Injuries Compensation Authority does not ask an applicant to provide their occupation when applying for compensation.

Centrally held information does not identify whether or not prosecutions were brought forward privately by victims of child sex abuse. To identify whether the relevant cases would require manual searching of court records, which would be of disproportionate cost.

Officials within my Department would be happy to extend an invitation to my Honourable Friend, the Member for Burton and Uttoxeter, to discuss what data is available and its limitations.

NHS England and NHS Improvement are using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England and NHS Improvement Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.

The NHS Business Services Authority is only able to provide information on prescriptions for cannabis-based medicines that have been dispensed and submitted to the NHS Business Services Authority. The NHS Business Services Authority does not hold information on prescriptions for cannabis-based medicines which have been issued but not fulfilled.

The following table shows the number of items for Nabilone and Sativex (licensed cannabis-based medicines) and unlicensed cannabis-based medicines that were prescribed on an NHS prescription, dispensed in the community and submitted to the NHS Business Services Authority for reimbursement since May 2018.

Note: * These figures represent prescribing of unlicensed cannabis-based medicines imported on a Home Office licence.

The following table shows the same products listed above covering the same time period but this data relates to private prescribing on an FP10PCD where the forms have been submitted to the NHS Business Services Authority for reporting and monitoring purposes only.

Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.

Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that, up until the end of March 2019, five patients have had private prescriptions issued for a cannabis-based product for medicinal use in independent secondary/tertiary care in England.

145 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.